The lung is a common site of complications of systemic connective tissue disease (CTD),
and lung involvement can present in several ways. Interstitial lung disease (ILD) and …

Sleep-related breathing disorders (SBDs) include obstructive apnoea, central apnoea and
sleep-related hypoventilation. These nocturnal events have the potential to increase …

Interstitial lung diseases are a group of diffuse parenchymal lung disorders associated with
substantial morbidity and mortality. Knowledge achieved in recent years has resulted in the …

Idiopathic pulmonary fibrosis (IPF) is a devastating disease, with a median survival as short
as 3 years from the time of diagnosis and no pharmacological therapies yet approved by the …

Obstructive sleep apnea (OSA) is a highly prevalent disorder that has profound implications
on the outcomes of patients with chronic lung disease. The hallmark of OSA is a collapse of …

Despite the development of pharmacological therapies that are effective in slowing the
progression of idiopathic pulmonary fibrosis (IPF), it remains a debilitating and lethal …

Idiopathic pulmonary fibrosis (IPF), a chronic and progressive fibrosing interstitial
pneumonia, is a fatal lung disease with a median survival time of 3–5 years. Problems in …

Study objectives The most recent idiopathic pulmonary fibrosis (IPF) guidelines include
obstructive sleep apnea (OSA) among the IPF-associated comorbidities. Furthermore, they …

Abstract Purpose of Review Idiopathic pulmonary fibrosis (IPF) is an invariably progressive
disease. Current treatment options simply slow disease progression, and better therapeutic …

Idiopathic pulmonary fibrosis (IPF) is a fibrotic lung disease of unknown cause characterized
by relentlessly progressive restrictive-ventilatory limitation, hypoxia, dyspnea, and cough …